Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy

Aims: To construct a predictive model for overall survival (OS) in unresectable pancreatic cancer (PaC) undergoing systemic chemotherapy and to confirm its accuracy in an independent cohort. Patients and methods: The training set (Ts) and the validation set (Vs) included 93 patients (median age=71 years) and 75 patients (median age=76 years). In the Ts, we examined variables linked to OS by uni- and multivariate analyses and constructed a predictive model for OS. Next, we evaluated the reproducibility of the proposed model in the Vs. Results: In the multivariate analysis for the Ts, PaC stage IV (P=0.0020) and carbohydrate antigen (CA) 19-9 ≥437.5 IU/l (P=0.0237) were identified to be significant factors associated with OS. Patients with PaC stage IV or not were given a score of 1 or 0, whereas patients with CA19-9 ≥437.5 IU/l or <437.5 IU/l were given a score of 1 or 0. Sum of the point of PaC stage (0 or 1) and CA19-9 (0 or 1) was defined as “PaC-CA score”. In the Ts, there were 16 patients with score 0, 40 with score 1 and 37 with score 2, while in the Vs, there were 9 patients with score 0, 32 with score 1 and 34 with score 2. Overall P values reached significance in the Ts (P=0.0002), the Vs (P=0.0029) and the combined Ts and Vs (P<0.0001) among patients with PaC score 0, 1 and 2. Conclusion: PaC-CA score can be helpful for risk stratification in PaC patients undergoing systemic chemotherapy.

[1]  Susan D Moffatt-Bruce,et al.  Computed Tomography-Assessed Skeletal Muscle Mass as a Predictor of Outcomes in Lung Cancer Surgery. , 2019, The Annals of thoracic surgery.

[2]  H. Muss,et al.  Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review , 2019, Breast Cancer Research and Treatment.

[3]  P. Philip,et al.  Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. , 2019, Cancer treatment reviews.

[4]  T. Naito Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia , 2019, Asia-Pacific journal of oncology nursing.

[5]  K. Roberts,et al.  Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  K. Pollard,et al.  The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice , 2019, Science.

[7]  Y. Ogata,et al.  Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer , 2019, AntiCancer Research.

[8]  Y. Fujiwara,et al.  Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

[9]  Rong Liu,et al.  Preoperative maximum standardized uptake value and carbohydrate antigen 19–9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma , 2019, BMC Cancer.

[10]  Eugene J Koay,et al.  Early Detection of Pancreatic Cancer: Opportunities and Challenges. , 2019, Gastroenterology.

[11]  T. Fujiwara,et al.  Clinical Impact of Sarcopenia on Gastric Cancer , 2019, AntiCancer Research.

[12]  M. Beuran,et al.  Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

[13]  W. Harmsen,et al.  Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[14]  G. Honda,et al.  Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients , 2019, BMC Cancer.

[15]  D. Jäger,et al.  Chemotherapy for pancreatic cancer. , 2019, Presse medicale.

[16]  P. Costelli,et al.  The Skeletal Muscle as an Active Player Against Cancer Cachexia , 2019, Front. Physiol..

[17]  A. Masamune,et al.  Advances in Early Detection of Pancreatic Cancer , 2019, Diagnostics.

[18]  C. Lu,et al.  Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model , 2019, Cancers.

[19]  E. Gallardo,et al.  Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study , 2018, BMC Cancer.

[20]  Wei Wang,et al.  A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC‐TNM staging , 2018, Surgery.

[21]  R. Takata,et al.  Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy. , 2017, Oncology letters.

[22]  M. Reni,et al.  A preoperative score to predict early death after pancreatic cancer resection. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  K. Shi,et al.  A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma , 2017, Journal of gastroenterology and hepatology.

[24]  T. Ohtsuka,et al.  Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis , 2017, Pancreas.

[25]  T. Kanai,et al.  Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy , 2017, Cancer Chemotherapy and Pharmacology.

[26]  S. Uemoto,et al.  Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. , 2016, Nutrition.

[27]  W. Ichikawa,et al.  Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX , 2016, Oncotarget.

[28]  L. Wood,et al.  Pancreatic cancer , 2016, The Lancet.

[29]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[30]  J. Hodson,et al.  A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[31]  Masao Tanaka,et al.  Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. , 2016, European journal of cancer.

[32]  Jarin Chindapasirt Sarcopenia in Cancer Patients. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[33]  K. Hanada,et al.  Diagnostic strategies for early pancreatic cancer , 2015, Journal of Gastroenterology.

[34]  J. Furuse,et al.  EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. , 2014, Japanese journal of clinical oncology.

[35]  Y. Inokawa,et al.  The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients , 2014, Surgery Today.

[36]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[37]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Chayama,et al.  Value of Cytodiagnosis Using Endoscopic Nasopancreatic Drainage for Early Diagnosis of Pancreatic Cancer: Establishing a New Method for the Early Detection of Pancreatic Carcinoma In Situ , 2012, Pancreas.

[39]  M. Mcphail,et al.  EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. , 2012, Gastrointestinal endoscopy.

[40]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[41]  Murray F. Brennan,et al.  Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.

[42]  N. Bardeesy,et al.  Pancreatic adenocarcinoma. , 2014, The New England journal of medicine.

[43]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.